Creative Planning purchased a new stake in LivaNova PLC (NASDAQ:LIVN) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 2,000 shares of the company’s stock, valued at approximately $248,000.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Retirement Systems of Alabama increased its stake in LivaNova by 11.2% in the 3rd quarter. Retirement Systems of Alabama now owns 62,747 shares of the company’s stock valued at $7,779,000 after purchasing an additional 6,300 shares in the last quarter. Fisher Asset Management LLC increased its position in LivaNova by 50.5% during the third quarter. Fisher Asset Management LLC now owns 245,378 shares of the company’s stock worth $30,420,000 after buying an additional 82,378 shares in the last quarter. First Quadrant L P CA increased its position in LivaNova by 62.4% during the third quarter. First Quadrant L P CA now owns 150,722 shares of the company’s stock worth $18,685,000 after buying an additional 57,931 shares in the last quarter. Texas Permanent School Fund increased its position in LivaNova by 8.7% during the third quarter. Texas Permanent School Fund now owns 30,574 shares of the company’s stock worth $3,790,000 after buying an additional 2,440 shares in the last quarter. Finally, Empowered Funds LLC purchased a new position in LivaNova during the third quarter worth $1,627,000. 87.38% of the stock is owned by institutional investors and hedge funds.
Several equities analysts have weighed in on LIVN shares. BidaskClub downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 18th. Stifel Nicolaus raised their price target on LivaNova from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Monday, September 17th. Needham & Company LLC reissued a “buy” rating and set a $135.00 price target (up previously from $128.00) on shares of LivaNova in a research report on Wednesday, August 1st. Jefferies Financial Group raised their price target on LivaNova to $150.00 and gave the stock a “buy” rating in a research report on Tuesday, October 2nd. Finally, Zacks Investment Research downgraded LivaNova from a “buy” rating to a “hold” rating in a research report on Thursday, September 20th. Three analysts have rated the stock with a hold rating, three have given a buy rating and two have assigned a strong buy rating to the company’s stock. LivaNova presently has an average rating of “Buy” and a consensus target price of $126.50.
LivaNova stock opened at $118.81 on Friday. The company has a quick ratio of 1.21, a current ratio of 1.65 and a debt-to-equity ratio of 0.06. The firm has a market cap of $5.97 billion, a price-to-earnings ratio of 35.89, a P/E/G ratio of 3.68 and a beta of 0.94. LivaNova PLC has a fifty-two week low of $76.14 and a fifty-two week high of $131.54.
LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, October 31st. The company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.08). The company had revenue of $272.10 million for the quarter, compared to analysts’ expectations of $275.03 million. LivaNova had a positive return on equity of 8.77% and a negative net margin of 8.31%. The business’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.83 EPS. On average, research analysts anticipate that LivaNova PLC will post 3.1 EPS for the current year.
In other news, Director Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $121.58, for a total value of $121,580.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider David S. Wise sold 1,500 shares of LivaNova stock in a transaction on Monday, October 15th. The shares were sold at an average price of $112.83, for a total value of $169,245.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 9,058 shares of company stock valued at $1,078,683. Company insiders own 0.41% of the company’s stock.
WARNING: “Creative Planning Purchases New Holdings in LivaNova PLC (LIVN)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/11/11/creative-planning-purchases-new-holdings-in-livanova-plc-livn.html.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Featured Article: Capital gains and your 401(k) or IRA
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.